MarketCap
Facebook
X
Telegram
Ayala Pharmaceuticals P/S Ratio | AYLA
Annual P/S Ratio Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.2 | 23.3 | 34.5 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34.5 | 11.2 | 23 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
30 | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Bicycle Therapeutics plc
BCYC
|
4.84 | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
1.78 | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
7.29 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
3.2 | - | - | $ 401 M | USA |
 |
BioLineRx Ltd.
BLRX
|
4.78 K | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
3.63 | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
54.5 | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
35.7 | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Genocea Biosciences
GNCA
|
44.3 | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
6.73 | $ 3.63 | 3.93 % | $ 795 M | Britain |
 |
Amryt Pharma plc
AMYT
|
11.4 | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
2.1 | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
11.9 | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
8.57 | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
6.5 | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
1.57 | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
2.12 | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
24.1 | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
4.97 | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
5.36 | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
12.8 | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
43.3 | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.32 K | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
1.96 | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Фармсинтез
LIFE
|
5.39 | - | - | - |  Russia |
 |
IMV
IMV
|
48.2 | - | - | $ 13.1 M | Canada |
 |
Karuna Therapeutics
KRTX
|
18 K | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
47.2 | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
534 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
6.81 | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
4.93 | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
320 | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
2.86 | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
1 | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
0.00146 | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.25 K | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
|
Champions Oncology
CSBR
|
1.41 | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
60.1 | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
1.07 | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
366 | $ 1.72 | 2.38 % | $ 13.8 M | USA |